CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML

Phase 2ziftomenibPositive
AI Analysis

Summary

Kyowa Kirin and Kura Oncology have initiated a Japanese Phase II registrational study of ziftomenib in adult patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Clinical Trial Data

Phase

Phase II

Importance:6/10
Sentiment:
0.50
oncologyAMLregistrational studyJapanNPM1-mutated
Related Companies

Read the original article

Published by Clinical Trials Arena on April 27, 2026 8:55 AM

Read Original